Nurix Therapeutics, Inc. (NRIX)

NASDAQ: NRIX · IEX Real-Time Price · USD
8.32
-0.20 (-2.35%)
At close: Sep 27, 2023, 4:00 PM
8.40
+0.08 (0.96%)
After-hours: Sep 27, 2023, 7:43 PM EDT
-2.35%
Market Cap 401.02M
Revenue (ttm) 60.94M
Net Income (ttm) -157.44M
Shares Out 48.20M
EPS (ttm) -2.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 335,046
Open 8.53
Previous Close 8.52
Day's Range 8.26 - 8.67
52-Week Range 8.12 - 15.09
Beta 1.61
Analysts Strong Buy
Price Target 27.56 (+231.25%)
Earnings Date Oct 9, 2023

About NRIX

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casita... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 297
Stock Exchange NASDAQ
Ticker Symbol NRIX
Full Company Profile

Financial Performance

In 2022, NRIX's revenue was $38.63 million, an increase of 29.84% compared to the previous year's $29.75 million. Losses were -$180.36 million, 53.9% more than in 2021.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for NRIX stock is "Strong Buy." The 12-month stock price forecast is $27.56, which is an increase of 231.25% from the latest price.

Price Target
$27.56
(231.25% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Nurix Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat pati...

27 days ago - GlobeNewsWire

Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

Announced Phase 1b expansion cohorts for NX-2127 in non-Hodgkin's lymphomas Presented data highlighting the potent cellular activity of both NX-5948 and NX-2127 against BTKi resistance mutations Recei...

2 months ago - GlobeNewsWire

Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications

Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma (DLBCL) was informed by a rapid and sustained complete response; Phase 1b expansion cohort also initiated...

3 months ago - GlobeNewsWire

Nurix Therapeutics to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

SAN FRANCISCO, May 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patie...

5 months ago - GlobeNewsWire

Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations

Oral presentation features structural disclosure and preclinical characterization of  NX-2127, Nurix's lead BTK degrader for the treatment of B-cell malignancies

5 months ago - GlobeNewsWire

Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

Licensed to Gilead a new development candidate, NX-0479/GS-6791, a targeted protein degrader of IRAK4, resulting in a $20 million payment

5 months ago - GlobeNewsWire

Nurix Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

SAN FRANCISCO, April 11, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat pat...

6 months ago - GlobeNewsWire

Nurix's stock rallies on Gilead's option

Shares of Nurix Therapeutics Inc. NRIX, -0.99% gained about 6% in premarket trading on Monday after Gilead Sciences Inc. GILD, -3.18% said it exercised the option to exclusively license Nurix's target...

Other symbols: GILD
6 months ago - Market Watch

Gilead Exercises Option to License Nurix's IRAK4 Targeted Protein Degrader Development Candidate, NX-0479

FOSTER CITY, Calif. & SAN FRANCISCO--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted p...

Other symbols: GILD
6 months ago - Business Wire

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting

Nurix to report additional preclinical data for its targeted BTK degraders NX-2127 and NX-5948 Nurix to report additional preclinical data for its targeted BTK degraders NX-2127 and NX-5948

7 months ago - GlobeNewsWire

Nurix Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

SAN FRANCISCO, March 06, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat pat...

7 months ago - GlobeNewsWire

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update

Demonstrated NX-2127 overcomes BTK inhibitor resistance mutations and provides clinical benefit to patients with hematological malignancies

8 months ago - GlobeNewsWire

Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities

Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its DELigase platform

9 months ago - GlobeNewsWire

Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat pati...

9 months ago - GlobeNewsWire

Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

NX-5948 is being evaluated in patients with relapsed and refractory B-cell malignancies

10 months ago - GlobeNewsWire

Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting

Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia (CLL) patients regardless of Bruton's tyrosine kinase (BTK) mutational status

10 months ago - GlobeNewsWire

Nurix Therapeutics Announces Webcast to Review Data from its Phase 1 Clinical Trial of BTK Degrader, NX-2127, Presented at the 64th American Society of Hematology Annual Meeting

Webcast Scheduled for Monday, December 12, 2022 at 8:30 PM CT (9:30 PM ET) Webcast Scheduled for Monday, December 12, 2022 at 8:30 PM CT (9:30 PM ET)

10 months ago - GlobeNewsWire

Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in

Presentations highlight use of Nurix's first-in-class CBL-B inhibitor NX-0255 to enhance growth and profile of T cells for cell therapy in DeTIL-0255 program Presentations highlight use of Nurix's fir...

11 months ago - GlobeNewsWire

Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies

Biomarker results are a positive demonstration of target engagement for this first-in-class  CBL-B inhibitor

11 months ago - GlobeNewsWire

Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

Nurix to provide a clinical update from the ongoing Phase 1 trial of NX-2127 in patients with hematologic malignancies Nurix to provide a clinical update from the ongoing Phase 1 trial of NX-2127 in p...

11 months ago - GlobeNewsWire

Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin's Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit

Complete response observed and ongoing in a patient with multiply relapsed/refractory diffuse large B cell lymphoma (DLBCL)

1 year ago - GlobeNewsWire

Nurix Therapeutics Announces Presentations at the 5th Annual Targeted Protein Degradation (TPD) Summit

SAN FRANCISCO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that ...

1 year ago - GlobeNewsWire

Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update

Completed two registered direct offerings in July raising gross proceeds of $95 million

1 year ago - GlobeNewsWire

Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors

SAN FRANCISCO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced the ...

1 year ago - GlobeNewsWire

Nurix Therapeutics Announces $40 Million Registered Direct Offering

SAN FRANCISCO, July 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that ...

1 year ago - GlobeNewsWire